Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome
Michaela Nováková,
Markéta Žaliová,
Martina Suková,
Marcin Wlodarski,
Aleš Janda,
Eva Froňková,
Vít Campr,
Kateřina Lejhancová,
Ondřej Zapletal,
Dagmar Pospíšilová,
Zdeňka Černá,
Tomáš Kuhn,
Peter Švec,
Vendula Pelková,
Zuzana Zemanová,
Gitte Kerndrup,
Marry van den Heuvel-Eibrink,
Vincent van der Velden,
Charlotte Niemeyer,
Tomáš Kalina,
Jan Trka,
Jan Starý,
Ondřej Hrušák,
Ester Mejstříková
Affiliations
Michaela Nováková
CLIP-Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Markéta Žaliová
CLIP-Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Martina Suková
Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Marcin Wlodarski
Center for Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany
Aleš Janda
Center for Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany
Eva Froňková
CLIP-Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic;Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Vít Campr
Department of Pathology and Molecular Medicine, University Hospital Motol, Prague, Czech Republic
Kateřina Lejhancová
Department of Pediatrics, Charles University, University Hospital Hradec Králové, Czech Republic
Ondřej Zapletal
Department of Pediatric Hematology, Children’s University Hospital, Brno, Czech Republic
Dagmar Pospíšilová
Department of Pediatrics, Palacky University and University Hospital Olomouc, Czech Republic
Zdeňka Černá
Department of Pediatrics, University Hospital Pilsen, Czech Republic
Tomáš Kuhn
Department of Pediatrics Ostrava, University Hospital Ostrava, Czech Republic
Peter Švec
Department of Pediatric Hematology and Oncology, University Hospital Bratislava, Slovakia
Vendula Pelková
CLIP-Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Zuzana Zemanová
Centre of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine and General University Hospital and Charles University, Prague, Czech Republic
Gitte Kerndrup
Department of Pathology, Aarhus University Hospital, Denmark
Marry van den Heuvel-Eibrink
Department of Pediatric Oncology, Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands
Vincent van der Velden
Department of Immunology, Erasmus MC, Rotterdam, the Netherlands
Charlotte Niemeyer
Center for Pediatrics and Adolescent Medicine, University Medical Center, Freiburg, Germany
Tomáš Kalina
CLIP-Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Jan Trka
CLIP-Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic;Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Jan Starý
Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Ondřej Hrušák
CLIP-Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic;Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Ester Mejstříková
CLIP-Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic;Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
GATA-2 deficiency was recently described as common cause of overlapping syndromes of immunodeficiency, lymphedema, familiar myelodysplastic syndrome or acute myeloid leukemia. The aim of our study was to analyze bone marrow and peripheral blood samples of children with myelodysplastic syndrome or aplastic anemia to define prevalence of the GATA2 mutation and to assess whether mutations in GATA-2 transcription factor exhibit specific immunophenotypic features. The prevalence of a GATA2 mutation in a consecutively diagnosed cohort of children was 14% in advanced forms of myelodysplastic syndrome (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and myelodysplasia-related acute myeloid leukemia), 17% in refractory cytopenia of childhood, and 0% in aplastic anemia. In GATA-2-deficient cases, we found the most profound B-cell lymphopenia, including its progenitors in blood and bone marrow, which correlated with significantly diminished intronRSS-Kde recombination excision circles in comparison to other myelodysplastic syndrome/aplastic anemia cases. The other typical features of GATA-2 deficiency (monocytopenia and natural killer cell lymphopenia) were less discriminative. In conclusion, we suggest screening for GATA2 mutations in pediatric myelodysplastic syndrome, preferentially in patients with impaired B-cell homeostasis in bone marrow and peripheral blood (low number of progenitors, intronRSS-Kde recombination excision circles and naïve cells).